Biovian Invests €50 Million in Manufacturing Facility in Finland

News
Article

The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025.

Biovian Oy announced a major investment of over €50 million to expand its manufacturing facility in Turku, Finland on July 26, 2023. The new facility plans to include house cutting-edge equipment and advanced technologies to support Advanced Therapy Medicinal Products (ATMP), such as adenoviral and adeno-associated viral (AAV) therapies.

According to the press release, it will feature dedicated Class A to D cleanroom areas for bulk drug substances and final drug product manufacture. Additionally, the expanded facility will follow current good manufacturing practices (cGMP) and fulfill both EU and US GMP requirements.

The expansion project is aimed to be completed in December 2024 and the new facility will be fully operational by 2025. Further, the investment hopes to create 100 job opportunities in the region.

Source: Biovian

Recent Videos
Drug Digest: Strategic Partnerships
Michelle Bridenbaker from Unbiased Science discusses her thoughts on the key industry from 2024 and those she anticipates will impact the industry in 2025 and beyond.
Henny Zijlstra from Adragos Pharma chats about the trends affecting the outsourcing market, various strategies being employed by service providers, and the value of end-to-end services.
Related Content